Prime Therapeutics Hires New CEO To Lead Pharmacy Benefit Combination With MagellanRx

  • 📰 Forbes
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Prime Therapeutics, a pharmacy benefit manager owned by several Blue Cross and Blue Shield health insurers, promoted Mostafa Kamal to succeed the retiring Ken Paulus as chief executive officer.

Prime is owned by 19 Blue Cross and Blue Shield Plans and manages the pharmacy benefits of nearly 38 million health plan members across the U.S. Prime’s board indicated Kamal is the right executive to grow the larger company.

“Mostafa’s vision for what we can become is inspiring and bold,” Maurice Smith, Prime’s board chairman who is also president and CEO of one Prime’s major owners, Health Care Service Corporation, the parent of five Blue Cross and Blue Shield plans, said Wednesday in announcing Kamal as the new CEO. “As Prime seeks to reimagine pharmacy benefit management, he is the right person to build on the strong foundation Ken leaves as he retires.

It’s a critical time for PBMs, which are hired by employers, health plans and government health programs to manage the rising costs of prescription drugs. Increasingly, just a small share of prescription drug claims account for most of the total spending on prescriptions thanks to expensive drugs derived from biotechnology.

But these days PBMs are poised to make a difference as less expensive copycat drugs known as “biosimilars” are developed as alternatives to the much more expensive brand name. PBMs are working to shift patients to biosimilars that work just as well as the brands.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 394. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Sarepta Therapeutics completes sale of priority review voucher for $102 millionSarepta Therapeutics Inc. said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the...
Source: MarketWatch - 🏆 3. / 97 Read more »